This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Wilson ECF, Jayne DRW, Dellow E, Fordham RJ.The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. Rheumatology 46: 1096-1101, No. 7, Jul 2007
Rights and permissions
About this article
Cite this article
MMF dominant as first-line therapy for lupus nephritis. Pharmacoecon. Outcomes News 538, 4 (2007). https://doi.org/10.2165/00151234-200705380-00011
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705380-00011